deltatrials
Completed PHASE2 NCT00668811

Sutent Adjunctive Treatment of Differentiated Thyroid Cancer

Sponsor: Medstar Health Research Institute

Conditions Differentiated Thyroid Cancer Follicular Thyroid Cancer Papillary Thyroid Cancer
Interventions SU011248, Sutent
Updated 12 times since 2017 Last updated: Aug 3, 2020 Started: Apr 30, 2008 Primary completion: Sep 30, 2015 Completion: Dec 31, 2015

This PHASE2 trial investigates Differentiated Thyroid Cancer and Follicular Thyroid Cancer and is currently completed. Medstar Health Research Institute leads this study, which shows 12 recorded versions since 2008 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

12 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE2

  5. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2

▶ Show 7 earlier versions

  1. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE2

  2. Sep 2020 — Jan 2021 [monthly]

    Completed PHASE2

  3. Jul 2018 — Sep 2020 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jul 2018 [monthly]

    Completed PHASE2

  5. May 2018 — Jun 2018 [monthly]

    Completed PHASE2

  6. Feb 2017 — May 2018 [monthly]

    Completed PHASE2

  7. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Apr 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Medstar Health Research Institute
  • Pfizer
Data source: Medstar Health Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Washington D.C., United States